Zolgensma, the gene therapy, developed and marketed by the pharmaceutical company Novartis, won both FDA approval and the title of "world's most expensive drug" earlier this year. However, it's recently come to light that Novartis knowingly provided the FDA manipulated data during the approval process. Dr. Chris Gerry explains what went wrong, why this is such a big deal, and whether Zolgensma should stay on the market.
